Previous issue | Volume 94 | ESPE2021

59th Annual ESPE (ESPE 2021 Online)

Online,
22 Sep 2021 - 26 Sep 2021

Card image cap
The 59th ESPE Annual Meeting will now be held online in September 2021.

ePoster Category 1

Growth Hormone and IGFs A

The impact of lockdown regulations caused by the COVID-19 pandemic on adherence to recombinant human growth hormone therapy: Evidence from real-world data
1The Netherlands Organization for Applied Scientific Research TNO, Leiden, Netherlands; 2Connected Health & Devices, Global Healthcare Operations, Ares Trading S.A., Eysins, Switzerland; 3Global Medical Affairs Cardiometabolic & Endocrinology, Merck KGaA, Darmstadt, Germany
hrp0094p1-131
Use of growth hormone therapy in short patients born small for gestational age: data from real-life French clinical practice
1University Hospital Angers, Angers, France; 2Medical School and University Hospital of the University of Lorraine, Nancy, France; 3Lyon University Pediatric Hospital, Lyon, France; 4Children’s Hospital, Toulouse University Hospital, Toulouse, France
hrp0094p1-132
Efficacy and safety profile of recombinant insulin like growth factor 1 (rh IGF1) therapy: A long term follow up study at a single tertiary centre.
1Department of Paediatric Endocrinology, Great Ormond Street Hospital, London, United Kingdom; 2Department of Paediatric Endocrinology & Diabetes, The Children’s Hospital & The Institute of Child Health, Lahore, Pakistan; 3Department of Paediatric Endocrinology and Diabetes, The Royal London Children’s Hospital, London, United Kingdom
hrp0094p1-133
Starting recombinant human growth hormone treatment at an early age improves adherence and catch-up growth in patients with growth disorders, and highlights the importance of the new guideline on referral of short children to paediatric care
1The Netherlands Organization for Applied Scientific Research TNO, Leiden, Netherlands; 2Leiden University Medical Centre, Leiden, Netherlands; 3Connected Health & Devices, Global Healthcare Operations, Ares Trading S.A., Eysins, Switzerland; 4Global Medical Affairs Cardiometabolic & Endocrinology, Biopharma, Merck KGaA, Darmstadt, Germany
hrp0094p1-134
Long-term safety of growth hormone in adults and adolescents with growth hormone deficiency: An overview of the full-cohort in KIMS
1Sahlgrenska University Hospital, Göteborg, Sweden; 2Sorbonne Université, Paris, France; 3Copenhagen University Hospital, Copenhagen, Denmark; 4Institute of Health Carlos III (ISCIII), Madrid, Spain; 5Hospital General Universitario de Alicante-Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain; 6Miguel Hernández University, Elche, Spain; 7Medical University of Vienna, Vienna, Austria; 8Pfizer, New York, USA; 9University of Groningen, Groningen, Netherlands; 10Pfizer, Brussels, Belgium; 11University of Arizona College of Medicine, Phoenix, USA
hrp0094p1-135
Comparison of actual GH dose with labeled dose in children with short stature based on the LG Growth Study
1Ajou University School of Medicine, Suwon, Republic of Korea; 2Konkuk University School of Medicine, Seoul, Republic of Korea; 3Korea University College of Medicine, Ansan, Republic of Korea; 4Seoul National University Bundang Hospital, Seongnam, Republic of Korea; 5Yonsei University College of Medicine, Seoul, Republic of Korea; 6Asan Medical Center, Seoul, Republic of Korea; 7Seoul National University College of Medicine, Seoul, Republic of Korea; 8College of Medicine, Chungnam National University, Sejong, Republic of Korea; 9College of Medicine, Hallym University, Seoul, Republic of Korea
hrp0094p1-136
Persistently increased IGF-I levels and excellent auxological response despite low doses of recombinant growth hormone in a GH-deficient patient with a heterozygous variant of the growth hormone receptor (GHR) gene
1Paediatric Department, Università degli Studi di Milano-Bicocca, Fondazione MBBM, Ospedale San Gerardo, Monza, Italy; 2Department, Università degli Studi di Milano-Bicocca, Fondazione MBBM, Ospedale San Gerardo, Monza, Italy; 3Paediatric Department, Università degli Studi di Milano-Bicocca, Fondazione MBBM, Monza, Italy
hrp0094p1-137
Safety and effectiveness of pediatric growth hormone therapy: Results from the full cohort in KIGS
1University of Genova, Genova, Italy; 2University Children´s Hospital, Tübingen, Germany; 3Children’s Hospital Los Angeles, Los Angeles, USA; 4Aglaia Kyriakou Children’s Hospital, Athens, Greece; 5Friedrich-Alexander University of Erlangen-Nürnberg, Erlangen, Germany; 6University of Gothenburg, Gothenburg, Sweden; 7Sant Joan de Déu, Barcelona, Spain; 8Health Institute Carlos III, Madrid, Spain; 9Pfizer, New York, USA; 10Liggins Institute, University of Auckland, Auckland, New Zealand; 11PendoCon, Putte, Belgium; 12Pfizer, Brussels, Belgium; 13AP-HP, Paris, France; 14Polish Mother’s Memorial Hospital-Research Institute, Lodz, Poland; 15Medical University of Lodz, Lodz, Poland; 16Université Paris Descartes; Hopital Necker Enfants Malades, Paris, France; 17The Children’s Hospital of Philadelphia, Philadelphia, USA
hrp0094p1-138